Luminor Changes Its Name to RISE Life Science Corp.Toronto, Ontario--(Newsfile Corp. - March 9, 2018) - Luminor Medical
Technologies (CSE: LMT), further to the acquisition of RISE Research Inc.,
announced today that it changed its corporate name to RISE Life Science Corp.
which was approved at the Company's annual and special shareholder meeting
(the 'Shareholder Meeting') held on Tuesday February 27, 2018. The Company has
reserved the stock symbol 'RLSC' and will commence trading under this symbol
upon approval by the Canadian Securities Commission.
'The name change reflects our emphasis on developing and evolving medical
cannabis-based formulations to create general use health and well-being
products for the emerging consumer category made possible by the legalization
of cannabis.' said Anton Mattadeen, CEO, RISE Life Science Corp.
In addition, the Shareholder Meeting saw three new additions to the Board of
Directors including Mr. Chris Dollard, Ms. Constance Finley and Mr. Michael
Campbell.
Mr. Dollard is COO of RISE Life Science Corp. Previously, he served as COO of
RISE Research Inc. since its inception in the fall of 2015. He also brings to
RISE Life Science Corp. a wealth of knowledge and experience from his work
related to operational planning and facility design pertaining to early
cannabis producer applications. Before entering the cannabis industry in late
2012, Mr. Dollard built a 25+ year career in the information technology
industry with Fortune 500 companies such as Deloitte, Accenture, IBM and Best
Buy, as well as many smaller firms and startups.
Ms. Finley is the founder and President of Constance Therapeutics, a San
Francisco-based company that produces whole plant medicinal cannabis extracts
for physicians and their patients. She is recognized as an industry leader and
is a frequent speaker at leading industry conferences including CannaTech,
SXSW, The California Academy of Sciences, the Cure Cancer Now Summit,
CWCBExpo, and the Cannabis Quality Strategies and Solutions Summit. She sits
on various advisory boards, including an assignment to the Scientific Advisory
Board for CannaTech.
Mr. Campbell is General Counsel and Corporate Secretary of
Intellipharmaceutics International Inc., a pharmaceutical company specializing
in the research, development and manufacture of novel and generic controlled
and targeted release oral solid dosage drugs. He previously served as General
Counsel for Griffis Capital and Canada Cartage System L.P.
It was also announced that Mr. Harry Bloomfield, who has served as Chairperson
of Luminor Medical Technologies Board of Directors, has retired from the
Board. Anton Mattadeen has been elected as Chairperson of the Board of
Directors.
'Mr. Bloomfield's insights during his tenure as Chairman, helped to
significantly move the company forward.' said Anton Mattadeen. 'We wish to
thank him for his leadership.'
RISE Life Science Corp. is pleased to announce that Robert Lelovic CPA, CA has
joined the company as Chief Financial Officer. Mr. Lelovic replaces Chris
Carmichael who has filled this role during the transition period from Luminor
to RISE Life Science Corp. Mr. Lelovic graduated from York University in 1998
and has been a chartered accountant since 2001. He has extensive experience in
public company reporting, corporate governance and compliance. Mr. Lelovic is
the president of Robert Lelovic Professional Corporation, a company registered
with the Institute of CPA Ontario and the co-founder of Inlync.
'We would also like to offer our sincere thanks to Chris Carmichael for his
invaluable input into the creation of the company structure,' said Anton
Mattadeen. 'And look forward to working with him in the future.'
Finally, additional resolutions approved at the Shareholder Meeting included
the appointment of MNP LLP as auditor, re-approval of the Company's stock
option plan, change of registered address to 145 King Street West, Suite 210,
Toronto, ON M5H 1J8 and the reduction of paid up capital in connection with a
reorganization of the Corporation involving the distribution of all of the
Corporation's shares of its wholly owned subsidiary Scout Assessment Corp.
(the 'Scout Corp Distribution') to the Corporation's shareholders. The Scout
Corp. Distribution is subject to a number of conditions including the filing
of a prospectus with the Ontario Securities Commission, CSE approval and
approval by the Directors of the Company. Further details of the resolutions
can be found on the management information circular filed on www.sedar.com on
February 7, 2018.
For more information, please contact:
Mark Komonoski
mark@komonoski.com
877-255-8483
403-470-8384